The clinical benefit of CPT-11 combined with 5-FU/CF for patients with locally advanced or metastatic colorectal cancer
- VernacularTitle:伊立替康联合5-Fu/CF治疗晚期结直肠癌的临床受益分析
- Author:
Liya LI
;
Liqun JIA
;
Xue LI
;
Donggui WAN
;
Fei LI
;
Peiwen LI
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
drug therapy;
CPT-11;
clinical benefit;
5-FU;
CF
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Irinotecan(CPT-11) is a derivative of camptothecin,an inhibitor of DNA topoisomerase I.CPT-11 is oxidized to inactivated metabolites(including APC)by CyP3A enzymes and activated to SN-38 by Carboxylesterase-2(CES-2).CPT-11 has been shown to exhibit excellent antitumor activity against colorectal cancer.Our research is to evaluate the efficacy and toxicity of CPT-11 combined with 5-FU/CF in the treatment of advanced or metastatic colorectal cancer.Methods:thirty-two cases of advanced or metastatic colorectal cancer patients were treated,and thirty cases were evaluable for efficacy.of which 19 cases were grouped with one cycle every two weeks and 13 cases were grouped with one cycle every three weeks.Results:In 30 evaluable patients,2 cases had complete response,11 cases had partial response,14 cases had stable disease and 3 cases with progressive disease.The response rate of the whole group was 43.3% and the stability rate was 46.7%.The clinical beneficial response rate was 83.3%.Median time to progression was 7.2 months and median overall survival time was 13.8 months. Dose limiting toxicity was delayed diarrhea and neutropenia.There was no death during the treatment.Conclusions:CPT-11 combined with 5-Fu/CF is an effective and well tolerated regimen in the treatment of advanced or metastatic colorectal cancer.which can relieve symptoms and improve quality of life of the patients.It can be used as the first-line or second-line therapy for advanced or metastatic colorectal cancer.
